Dendreon (DNDN) Reports Mixed Q2 Results
More News related to DNDN
- Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
- Dendreon (DNDN) January volatility at 58, May at 99 into meeting
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Dendreon Receives FDA Acknowledgement of Complete Response
- Leerink Says Takeaway From Dendreon's (DNDN) Q3 Report is the Busy Preparations for Provenge
More News related to Earnings
- Highlights From SWHC Q2 Conference Call: First Qtr Reflected Results From Two Segments Under S&W Umbrella; Guides Below for Q3
- NASB Financial (NASB) Posts Q4 EPS of $0.77, Tops Views
- Highlights From Take-Two Interactive Softwares' (TTWO) Forecast Teleconference
- Saks (SKS) Restates Q3 EPS to $0.04, Up from $0.01
- Big Lots (BIG) Delivers With Strong Q3 Results and Guidance
Dendreon (Nasdaq: DNDN) reports Q2 loss of $0.18, 4 cents better than the analyst estimate of ($0.22). Revenues for the quarter were $26k, versus the consensus of $70k.
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that harness the immune system to fight cancer.
Related Categories
EarningsStocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
